Amisulpride - Acacia Pharma

Drug Profile

Amisulpride - Acacia Pharma

Alternative Names: APD-403; APD-421; BAREMSISTM

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acacia Pharma
  • Class Antidepressants; Antiemetics; Antipsychotics; Benzamides; Pyrrolidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative nausea and vomiting
  • Phase II Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 01 Jan 2017 Acacia Pharma completes a phase III trial for Post operative nausea and vomiting in USA, France and Germany (NCT02646566)
  • 31 Aug 2016 Acacia Pharma completes a phase I pharmacokinetics trial in Healthy volunteers in Netherlands (IV) (NCT02881840)
  • 12 Aug 2016 Acacia Pharma has patent protection for amisulpride usage
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top